Table of contents

CHAPTER 1 INTRODUCTION Page 1-6

CHAPTER 2 REVIEW OF LITERATURE Page 7-49

➢ 2.1 COMPLEMENT SYSTEM: ITS ACTIVATION, REGULATION AND BIOSYNTHESIS
  ➢ 2.1.1- Complement activation 7
  ➢ 2.1.2- Complement Regulation 9
  ➢ 2.1.3- Biosynthesis of plasma complements and expression of complement receptors in the liver 10

➢ 2.2 COMPLEMENT SYSTEM: RELEVANCE TO VIRAL BIOLOGY 11
  ➢ 2.2.1.a- Complement activation during virus infection 11
  ➢ 2.2.1.b- Virus opsonisation 12
  ➢ 2.2.1.c- Virolysis 13
  ➢ 2.2.1.d- Anaphylatoxin and chemotaxin production 13
  ➢ 2.2.1.e- Multifaceted effects of complement 14
  ➢ 2.2.2- Viral strategies to evade complement system
    ➢ 2.2.2.a- Incorporation of host complement regulatory proteins into virus envelopes 14
    ➢ 2.2.2.b- Prevention of complement activation by antibody–antigen complexes and viral Fc receptors 15
    ➢ 2.2.2.c- Virus-encoded proteins 15
Table of Contents

➤ 2.3 ROLE OF COMPLEMENTS IN DISORDERS PERTAINING TO LIVER
  ➤ 2.3.1- Liver fibrosis 17
  ➤ 2.3.2- Alcohol induced liver injury 17
  ➤ 2.3.3- Liver regeneration 18
  ➤ 2.3.4- Liver ischemia/reperfusion injury and transplantation 19
  ➤ 2.3.5- Viral hepatitis 21

➤ 2.4 HEPATITIS C VIRUS AND CHRONIC HEPATITIS C 22
  ➤ 2.4.1- Hepatitis C Virus 23
  ➤ 2.4.2- HCV genome structure and organization 24
    ➤ 2.4.2.1- 5' Untranslated region 24
    ➤ 2.4.2.2- 3'-Untranslated region 24
    ➤ 2.4.2.3- Structural proteins 25
      ➤ 2.4.2.3.a- Core protein 25
      ➤ 2.4.2.3.b- E1 and E2 envelope glycoproteins 26
      ➤ 2.4.2.3.c- Frameshift protein 26
    ➤ 2.4.2.4- Nonstructural proteins 26
      ➤ 2.4.2.4.a-P7 26
      ➤ 2.4.2.4.b- NS2 26
      ➤ 2.4.2.4.c- NS3-NS4A 27
      ➤ 2.4.2.4.d-NS4B 27
      ➤ 2.4.2.4.e -NS5A 27
  ➤ 2.4.3- Prevalence of hepatitis C 27
    ➤ 2.4.3.1- Prevalence of hepatitis C worldwide 27
    ➤ 2.4.3.2- Prevalence of hepatitis C in India 29
  ➤ 2.4.4- HCV infection 30
    ➤ 2.4.4.1- Acute Infection 31
### Table of Contents

- 2.4.4.2- Chronic Infection 32
- 2.4.5- Pathogenesis of HCV infection 32
  - 2.4.5.1.a- Adaptive immunity 33
  - 2.4.5.1.b- Innate immunity 34
  - 2.4.5.1.c- Role of genotype in treatment and disease progression 34
- 2.4.6- Immune system in Hepatitis C infection 36
  - 2.4.6.1- The Role of Humoral Innate Immunity in Hepatitis C Virus Infection: Special emphasis on the complement cascade 36
  - 2.4.6.2- Complement system subversion by Hepatitis C virus 38
- 2.4.7- Complement system mutation and manifestations 40

### CHAPTER 3 MATERIALS AND METHODS 50-95

- 3.1- Sample size estimation 49
- 3.2- Sample collection 51
- 3.3- Specialized Investigations 52
- 3.4- Serological tests 52
  - 3.4.1- IgM anti-HAV 52
  - 3.4.2- HBsAg 55
  - 3.4.3- IgM anti-HBc 59
  - 3.4.4- Anti-HCV 62
  - 3.4.5- IgM anti-HEV 67
- 3.5- Principle of PCR 70
  - 3.5.1- Allele Specific PCR amplification of CFH gene SNP 73
  - 3.5.2- Allele Specific PCR amplification of C4 gene SNP 73
  - 3.5.3- Allele Specific PCR amplification of C3 gene SNP 75
3.6- Expression study of C3, C4 and CFH.
   ➢ 3.6.1- Expression study of C3 77
   ➢ 3.6.2- Expression study of C4 79
   ➢ 3.6.3- Expression study of CFH 82

3.7- RNA Extraction 84
   ➢ 3.7.1- RNA purification 84
   ➢ 3.7.2- cDNA preparation 85

3.8- RT-PCR of C3, C4 and CFH gene 85

3.9- Viral RNA extraction 88
   ➢ 3.9.1- Detection of HCV RNA 88
   ➢ 3.9.2- Detection of PCR products 89

3.10- Quantification of HCV viral load by real time PCR 90

3.11- Genotyping of HCV 92

3.12- Statistical analysis 93

CHAPTER 4 RESULTS 96-178

➢ 4.1. SNP related deficiencies of complementary system components C4, CFH and C3 in HCV infected patients and healthy control will be investigated. 94

➢ 4.2. Quantification of complementary system components C4, CFH and C3 at mRNA level in HCV infected and control samples. 101

➢ 4.3. Determination of HCV genotypes and viral load among HCV infected patients. 106

➢ 4.4. Correlation of complement gene C4, CFH and C3 SNP’s, complementary system component levels, HCV viral load and genotype with disease progression in HCV infected patients and comparison with controls. 108
<table>
<thead>
<tr>
<th>CHAPTER 5</th>
<th>DISCUSSION</th>
<th>179-180</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHAPTER 6</td>
<td>SUMMARY</td>
<td>191-195</td>
</tr>
<tr>
<td>CHAPTER 7</td>
<td>CONCLUSION</td>
<td>196</td>
</tr>
<tr>
<td>APPENDIX I</td>
<td>REFERENCES</td>
<td>240-243</td>
</tr>
<tr>
<td>APPENDIX II</td>
<td>STUDY PROFORMA</td>
<td></td>
</tr>
<tr>
<td>APPENDIX III</td>
<td>APPROVAL LETTER OF THE ETHICAL COMMITTEE (MAMC)</td>
<td></td>
</tr>
<tr>
<td>APPENDIX IV</td>
<td>EXTRACTS, AWARDS AND PUBLICATION</td>
<td></td>
</tr>
<tr>
<td>APPENDIX V</td>
<td>MASTER CHART</td>
<td></td>
</tr>
</tbody>
</table>